---
document_datetime: 2025-12-29 08:31:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tavneos.html
document_name: tavneos.html
version: success
processing_time: 0.1141484
conversion_datetime: 2025-12-29 23:18:51.735154
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tavneos

[RSS](/en/individual-human-medicine.xml/67512)

##### Authorised

This medicine is authorised for use in the European Union

avacopan Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tavneos](#news-on)
- [More information on Tavneos](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tavneos is a medicine used to treat adults with severe, active granulomatosis with polyangiitis (GPA or Wegener's granulomatosis) or microscopic polyangiitis (MPA), which are inflammatory conditions of the blood vessels. Tavneos is used as part of a combined treatment also including the medicines rituximab or cyclophosphamide.

Tavneos contains the active substance avacopan.

GPA and MPA are rare, and Tavneos was designated an 'orphan medicine' (a medicine used in rare diseases). Further information on the orphan designations can be found on the European Medicines Agency's website ( [GPA](/en/medicines/human/orphan-designations/eu-3-14-1373) : 19 November 2014; [MPA](/en/medicines/human/orphan-designations/eu-3-14-1372) : 19 November 2014).

Expand section

Collapse section

## How is Tavneos used?

The medicine can only be obtained with a prescription. Treatment should be started and monitored by healthcare professionals experienced in the diagnosis and treatment of GPA or MPA.

The medicine is available as capsules and the recommended dose is 30 mg taken by mouth twice daily with meals. The doctor may have to interrupt or stop the treatment in case of certain severe side effects. Patients on Tavneos should avoid grapefruit and grapefruit juice as it can affect the way the medicine works.

For more information about using Tavneos, see the package leaflet or contact your doctor or pharmacist.

## How does Tavneos work?

The active substance in Tavneos, avacopan, blocks the receptor (target) for a protein in the blood called complement 5a (or C5a), which forms part of the immune system (the body's natural defences).

When C5a attaches to its receptor, it activates immune cells called neutrophils, which contribute to the inflammation of small blood vessels in GPA and MPA. By blocking the receptor for C5a, Tavneos is expected to reduce inflammation of blood vessels, thus improving the symptoms of the disease.

## What benefits of Tavneos have been shown in studies?

In a study of 330 patients with GPA or MPA, Tavneos was compared with high-dose corticosteroids (other medicines for inflammatory diseases). All patients received standard treatment with either rituximab or a regimen consisting of cyclophosphamide followed by azathioprine. All patients also received additional corticosteroids as needed.

After 26 weeks of treatment with Tavneos 72% (120 out of 166) of patients were in complete remission, compared with 70% (115 out of 164) of patients given corticosteroids at high doses for 20 weeks. At week 52, 66% (109 out of 166) of patients on Tavneos and standard therapy were still in remission, compared with 55% (90 out of 164) of patients given corticosteroids and standard therapy.

## What are the risks associated with Tavneos?

The most common side effects with Tavneos (which may occur in more than 1 in 10 people) are nausea (feeling sick), headache, decrease in white blood cell count, upper respiratory tract (nose and throat) infection, diarrhoea, vomiting, and nasopharyngitis (inflammation of the nose and throat).

The most common serious side effects are liver function abnormalities and pneumonia (infection of the lungs).

The full list of side effects and restrictions of Tavneos is presented in the package leaflet.

## Why is Tavneos authorised in the EU?

Tavneos was shown to be at least as effective as high-dose corticosteroids in inducing remission in patients with GPA or MPA and to lead to better long-term remission rates. Tavneos' safety profile is acceptable. Abnormalities in patients' liver function were the most serious side effects, and were considered manageable with appropriate guidance presented in the product information. There is a high unmet need for medicines to treat GPA and MPA that will allow doses of corticosteroids to be reduced. The European Medicines Agency therefore decided that Tavneos' benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tavneos?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tavneos have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tavneos are continuously monitored. Suspected side effects reported with Tavneos are carefully evaluated and any necessary action is taken to protect patients.

## Other information about Tavneos

Tavneos received a marketing authorisation valid throughout the EU on 11 January 2022.

Tavneos : EPAR - Medicine Overview

Reference Number: EMA/686677/2021

English (EN) (120.14 KB - PDF)

**First published:** 26/01/2022

[View](/en/documents/overview/tavneos-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-882)

български (BG) (141.01 KB - PDF)

**First published:**

26/01/2022

[View](/bg/documents/overview/tavneos-epar-medicine-overview_bg.pdf)

español (ES) (118.71 KB - PDF)

**First published:**

26/01/2022

[View](/es/documents/overview/tavneos-epar-medicine-overview_es.pdf)

čeština (CS) (141.24 KB - PDF)

**First published:**

26/01/2022

[View](/cs/documents/overview/tavneos-epar-medicine-overview_cs.pdf)

dansk (DA) (116.74 KB - PDF)

**First published:**

26/01/2022

[View](/da/documents/overview/tavneos-epar-medicine-overview_da.pdf)

Deutsch (DE) (120.68 KB - PDF)

**First published:**

26/01/2022

[View](/de/documents/overview/tavneos-epar-medicine-overview_de.pdf)

eesti keel (ET) (106.24 KB - PDF)

**First published:**

26/01/2022

[View](/et/documents/overview/tavneos-epar-medicine-overview_et.pdf)

ελληνικά (EL) (142.05 KB - PDF)

**First published:**

26/01/2022

[View](/el/documents/overview/tavneos-epar-medicine-overview_el.pdf)

français (FR) (119.5 KB - PDF)

**First published:**

26/01/2022

[View](/fr/documents/overview/tavneos-epar-medicine-overview_fr.pdf)

hrvatski (HR) (137.91 KB - PDF)

**First published:**

26/01/2022

[View](/hr/documents/overview/tavneos-epar-medicine-overview_hr.pdf)

italiano (IT) (117.12 KB - PDF)

**First published:**

26/01/2022

[View](/it/documents/overview/tavneos-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (146.61 KB - PDF)

**First published:**

26/01/2022

[View](/lv/documents/overview/tavneos-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (139.22 KB - PDF)

**First published:**

26/01/2022

[View](/lt/documents/overview/tavneos-epar-medicine-overview_lt.pdf)

magyar (HU) (140.81 KB - PDF)

**First published:**

26/01/2022

[View](/hu/documents/overview/tavneos-epar-medicine-overview_hu.pdf)

Malti (MT) (141.5 KB - PDF)

**First published:**

26/01/2022

[View](/mt/documents/overview/tavneos-epar-medicine-overview_mt.pdf)

Nederlands (NL) (117.33 KB - PDF)

**First published:**

26/01/2022

[View](/nl/documents/overview/tavneos-epar-medicine-overview_nl.pdf)

polski (PL) (143.87 KB - PDF)

**First published:**

26/01/2022

[View](/pl/documents/overview/tavneos-epar-medicine-overview_pl.pdf)

português (PT) (119.03 KB - PDF)

**First published:**

26/01/2022

[View](/pt/documents/overview/tavneos-epar-medicine-overview_pt.pdf)

română (RO) (137.62 KB - PDF)

**First published:**

26/01/2022

[View](/ro/documents/overview/tavneos-epar-medicine-overview_ro.pdf)

slovenčina (SK) (139.48 KB - PDF)

**First published:**

26/01/2022

[View](/sk/documents/overview/tavneos-epar-medicine-overview_sk.pdf)

slovenščina (SL) (136.53 KB - PDF)

**First published:**

26/01/2022

[View](/sl/documents/overview/tavneos-epar-medicine-overview_sl.pdf)

Suomi (FI) (115.5 KB - PDF)

**First published:**

26/01/2022

[View](/fi/documents/overview/tavneos-epar-medicine-overview_fi.pdf)

svenska (SV) (116.23 KB - PDF)

**First published:**

26/01/2022

[View](/sv/documents/overview/tavneos-epar-medicine-overview_sv.pdf)

Tavneos : EPAR - Risk management plan

English (EN) (725.3 KB - PDF)

**First published:** 26/01/2022

**Last updated:** 06/01/2025

[View](/en/documents/rmp/tavneos-epar-risk-management-plan_en.pdf)

## Product information

Tavneos : EPAR - Product Information

English (EN) (303.84 KB - PDF)

**First published:** 26/01/2022

**Last updated:** 31/01/2025

[View](/en/documents/product-information/tavneos-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-163)

български (BG) (492.84 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/bg/documents/product-information/tavneos-epar-product-information_bg.pdf)

español (ES) (467.05 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/es/documents/product-information/tavneos-epar-product-information_es.pdf)

čeština (CS) (474.96 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/cs/documents/product-information/tavneos-epar-product-information_cs.pdf)

dansk (DA) (288.32 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/da/documents/product-information/tavneos-epar-product-information_da.pdf)

Deutsch (DE) (375.37 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/de/documents/product-information/tavneos-epar-product-information_de.pdf)

eesti keel (ET) (340.44 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/et/documents/product-information/tavneos-epar-product-information_et.pdf)

ελληνικά (EL) (656.29 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/el/documents/product-information/tavneos-epar-product-information_el.pdf)

français (FR) (451.08 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/fr/documents/product-information/tavneos-epar-product-information_fr.pdf)

hrvatski (HR) (391.58 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/hr/documents/product-information/tavneos-epar-product-information_hr.pdf)

íslenska (IS) (292.24 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/is/documents/product-information/tavneos-epar-product-information_is.pdf)

italiano (IT) (321.24 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/it/documents/product-information/tavneos-epar-product-information_it.pdf)

latviešu valoda (LV) (441.11 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/lv/documents/product-information/tavneos-epar-product-information_lv.pdf)

lietuvių kalba (LT) (380.51 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/lt/documents/product-information/tavneos-epar-product-information_lt.pdf)

magyar (HU) (402.66 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/hu/documents/product-information/tavneos-epar-product-information_hu.pdf)

Malti (MT) (489.83 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/mt/documents/product-information/tavneos-epar-product-information_mt.pdf)

Nederlands (NL) (511.83 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/nl/documents/product-information/tavneos-epar-product-information_nl.pdf)

norsk (NO) (295.89 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/no/documents/product-information/tavneos-epar-product-information_no.pdf)

polski (PL) (414 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/pl/documents/product-information/tavneos-epar-product-information_pl.pdf)

português (PT) (286.49 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/pt/documents/product-information/tavneos-epar-product-information_pt.pdf)

română (RO) (462.76 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/ro/documents/product-information/tavneos-epar-product-information_ro.pdf)

slovenčina (SK) (430.94 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/sk/documents/product-information/tavneos-epar-product-information_sk.pdf)

slovenščina (SL) (391.42 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/sl/documents/product-information/tavneos-epar-product-information_sl.pdf)

Suomi (FI) (282.07 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/fi/documents/product-information/tavneos-epar-product-information_fi.pdf)

svenska (SV) (347.16 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

31/01/2025

[View](/sv/documents/product-information/tavneos-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00010967/202403 15/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tavneos : EPAR - All authorised presentations

English (EN) (50.44 KB - PDF)

**First published:** 26/01/2022

**Last updated:** 25/11/2022

[View](/en/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-383)

български (BG) (58.22 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/bg/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_bg.pdf)

español (ES) (50.79 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/es/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_es.pdf)

čeština (CS) (52.75 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/cs/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (51.36 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/da/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.5 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/de/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (48.51 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/et/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (54.04 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/el/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_el.pdf)

français (FR) (50.76 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/fr/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (52.26 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/hr/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (51.93 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/is/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_is.pdf)

italiano (IT) (50.22 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/it/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (53.66 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/lv/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (54.08 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/lt/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (54.81 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/hu/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (53.78 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/mt/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (48.93 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/nl/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (50.88 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/no/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_no.pdf)

polski (PL) (54.31 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/pl/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_pl.pdf)

português (PT) (50.8 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/pt/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.61 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/ro/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (55.63 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/sk/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (52.11 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/sl/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (48.03 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/fi/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (51.52 KB - PDF)

**First published:**

26/01/2022

**Last updated:**

25/11/2022

[View](/sv/documents/all-authorised-presentations/tavneos-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tavneos Active substance avacopan International non-proprietary name (INN) or common name avacopan Therapeutic area (MeSH)

- Microscopic Polyangiitis
- Wegener Granulomatosis

Anatomical therapeutic chemical (ATC) code L04

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).

## Authorisation details

EMA product number EMEA/H/C/005523

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Vifor Fresenius Medical Care Renal Pharma France

100-101 Terrasse Boieldieu

Opinion adopted 11/11/2021 Marketing authorisation issued 11/01/2022 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tavneos : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (173.36 KB - PDF)

**First published:** 25/11/2022

**Last updated:** 31/01/2025

[View](/en/documents/procedural-steps-after/tavneos-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tavneos-H-C-PSUSA-00010967/202403 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/517000/2024

English (EN) (181.02 KB - PDF)

**First published:** 31/01/2025

[View](/en/documents/scientific-conclusion/tavneos-h-c-psusa-00010967-202403-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

Tavneos : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/249662/2024

English (EN) (136.61 KB - PDF)

**First published:** 02/07/2024

[View](/en/documents/scientific-conclusion/tavneos-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

Tavneos-H-C-005523-P46-006 - EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/286099/2023

English (EN) (944.41 KB - PDF)

**First published:** 19/07/2023

[View](/en/documents/variation-report/tavneos-h-c-005523-p46-006-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Tavneos : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/708044/2021 Corr

English (EN) (3.19 MB - PDF)

**First published:** 27/01/2022

**Last updated:** 20/07/2023

[View](/en/documents/assessment-report/tavneos-epar-public-assessment-report_en.pdf)

Tavneos : EPAR - Orphan Medicine Assessment Report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-748110

English (EN) (301.55 KB - PDF)

**First published:** 27/01/2022

[View](/en/documents/orphan-maintenance-report/tavneos-epar-orphan-medicine-assessment-report-initial-authorisation_en.pdf)

CHMP summary of positive opinion for Tavneos

Adopted

Reference Number: EMA/CHMP/624375/2021

English (EN) (137.37 KB - PDF)

**First published:** 12/11/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tavneos_en.pdf)

#### News on Tavneos

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021) 12/11/2021

[First-in-class medicine recommended for treatment of rare blood vessel inflammation](/en/news/first-class-medicine-recommended-treatment-rare-blood-vessel-inflammation) 12/11/2021

#### More information on Tavneos

- [EU/3/14/1373 - orphan designation for treatment of granulomatosis with polyangiitis](/en/medicines/human/orphan-designations/eu-3-14-1373)
- [EU/3/14/1372 - orphan designation for treatment of microscopic polyangiitis (avacopan)](/en/medicines/human/orphan-designations/eu-3-14-1372)
- [EMEA-002023-PIP01-16-M07 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002023-pip01-16-m07)
- [Retrospective Cohort Study Evaluating Clinical Outcomes in Patients with Granulomatosis with Polyangiitis (GPA)/Microscopic Polyangiitis (MPA) Treated with Avacopan (20230026) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000065)
- [Avacostar - A Post Authorization Safety Study (PASS) to Evaluate the Incidence of Safety Events of Interest in Patients Treated With Avacopan for ANCAassociated Vasculitis (AAV) - post-authorisation study](https://catalogues.ema.europa.eu/study/106869)

**This page was last updated on** 31/01/2025

## Share this page

[Back to top](#main-content)